Vericel Corporation (VCEL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Vericel Corporation  (NASDAQ: VCEL)


Vericel's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Vericel's ROI in the second quarter of 2026?
Vericel Corporation achieved a return on average invested assets (ROI) of 5.58 % in its second quarter of 2026 a new company high.

ROI has improved compared to 5.11% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 138 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 1487 to 1501.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 14.84 % 15.86 % 17.44 % 19.82 % 21.54 %
Y / Y Net Income Change TTM 240.8 % 620.69 % 16.13 % - -
Investment (TTM) in Millions 450 438 439 408 394
Return On Investment (TTM) 5.58 % 5.11 % 4.06 % 3.33 % 1.88 %
VCEL's Overall Ranking # 1501 # 1487 # 1347 # 1416 # 1481
Seq. Investment Change TTM 3.33 % 3.28 % 3.59 % 3.88 % 4.24 %
Seq. Net Income Change TTM 12.86 % 29.93 % 26.27 % 84.07 % 138.65 %
Net Income (TTM) in Millions 24 21 17 13 7

VCEL Company Profile >> Back to VCEL Roi Comparisons >> See Annual VCEL Return On Investment



Return On Investment VCEL's Ranking
Within: No.
Industry # 16
Sector # 139
Overall # 1501

Return On Investment Statistics
High Average Low
5.58 %
-74.11 %
-821.12 %
(Jun 30 2026)   (Mar 31 2013)







Financial Statements
Vericel's II. Quarter Investments $ 450 Millions VCEL's Balance sheet
Vericel's II. Quarter Income $ 2 Millions Quarterly VCEL's Income Statement
VCEL's Income by Division See VCEL's Income by Division


VCEL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 439 382 308 236 218
Y / Y Investment Growth 14.74 % 24.2 % 30.72 % 8.22 % 18.85 %
Net Income in Millions 17 10 -3 -17 -7
Y / Y Net Income Growth 59.41 % - - - -
Annual Return On Investment 3.76 % 2.71 % -1.03 % -7.09 % -3.43 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 3.76 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VCEL's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VCEL's Competitors
Subscribers only: Roi for Vericel's Suppliers
Subscribers only: Return On Investment for VCEL's Customers

Other Ratios
VCEL's Roa VCEL's Inventory Turnover Ratio VCEL's Growth Rates VCEL's Dividend Statistics
VCEL's Profitability Ratios VCEL's Asset Turnover Ratio VCEL's Dividend Growth
VCEL's Roe VCEL's Valuation Ratios VCEL's Financial Strength Ratios VCEL's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Nephros Inc   15.31 %
West Pharmaceutical Services Inc   15.29 %
Progyny Inc   15.25 %
Biolife Solutions Inc   14.83 %
Sbc Medical Group Holdings Incorporated  14.78 %
Spero Therapeutics Inc   14.54 %
Insulet Corporation  14.30 %
Alpha Pro Tech Ltd   13.80 %
Bristol myers Squibb Company  13.58 %
Transmedics Group Inc   13.46 %
Strata Critical Medical Inc   13.34 %
Johnson and Johnson  13.30 %
Amgen Inc   13.08 %
Medinotec Inc   13.06 %
Lantheus Holdings Inc   13.02 %
Msa Safety Inc  13.02 %
Universal Health Services Inc   12.43 %
Ufp Technologies Inc   12.12 %
Solventum Corporation  11.98 %
Ligand Pharmaceuticals Incorporated  11.93 %
Lifevantage Corp  11.84 %
Regeneron Pharmaceuticals Inc   11.83 %
Protagonist Therapeutics inc   11.66 %
Encompass Health Corporation  11.56 %
Embecta Corp   11.20 %
Lemaitre Vascular Inc   11.20 %
3m Company  11.16 %
Globus Medical Inc   11.01 %
National Healthcare Corp  10.91 %
Bioventus Inc   10.85 %

Date modified: 2026-09-12T19:01:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.